At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 5 Investigator-Initiated clinical Trials (IIT) in 8 leading hospitals in China, with many pipeline projects have entered into IND application stage. Among them, gene editing projects for β-thalassemia, PD1 knockout non-viral targeted integration CAR-T and UCART have achieved excellent clinical results and have published several academic papers in famous academic journals such as Nature 、Nature Medicine and Nature biotechnology. BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms, and has a 7000 square meter GMP pilot plant and an operating team of nearly 200 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors!
Dedicated to the development and translation of gene editing and cell therapy and gene therapy for genetic diseases caused by gene mutations
More than 200 employees
Contains 15.19% PhD and 27.45% Master
Has applied for 125 invention patents at home and abroad
Has five core technology platforms with independent intellectual property rights
Relying on its strong technical strength and scientific research team in the field of gene editing and immunology, BRL Medicine is dedicated to the development and translation of gene editing and cell therapy, as well as gene therapy for genetic diseases caused by gene mutations.
BRL Medicine's gene therapy has successfully cured 6 cases of severe β thalassaemia
BRL Medicine was employed as the scientific research cooperative unit of rare diseases Professional Committee of Hunan Genetic Society
Collaboration with East China Normal University to set up
Cooperation with the 923 Hospital of the PLA Joint Logistic Support Force has successfully cured 3 cases of severe β thalassaemia for the first time in Guangxi
Collaboration with The First Affiliated Hospital, ZHEJIANG University, the first ALL patient of the new generation UCART was cured and discharged
BRL Medicine outstanding research results were selected into the second edition of
Launch of "Global Partner" introduction program
6000 square meters GMP pilot plant put into operation
First successful treatment of ALL patients using CD19-UCART in collaboration with The First Affiliated Hospital of Zhengzhou University
Obtained "Intellectual Property Management System Certification"
Collaborated with The First Affiliated Hospital, ZHEJIANG University to release clinical data on the world's first CD19-PD1-Quikin-CART for the successful treatment of lymphoma
Collaboration with Xiangya Hospital Central South University to release the world's first clinical data of CRISPR gene editing for the successful treatment of β0/β0 severe β thalassemia
Self-developed a new dual base editor system，published by Nature Biotechnology
Independently developed ultra-high activity HyCBE single-base editor，published by Nature Cell Biology
Next-generation single-base editing technology confirmed as promising cure for inherited blood disorders，published by Nature medicine
Awarded "2019 top 100 future medical · China list - UCAR-T TOP5"
Awarded tens of millions of dollars in funding support from the Shanghai Zhangjiang National Innovation Demonstration Zone Special Development Fund (H25)
Gene editing for thalassemia, CD19-PD1-Quikin-CART, and enhanced PSMA-CART successively initiated IIT
Awarded "2019 China's Top 50 Most Innovative Biomedical Companies"
Selected as a patent pilot enterprise in Shanghai in 2019
Gene Therapy Promises Complete Cure for Inherited Blood Disorders, published by Nature Medicine
CD19-UCART start IIT clinical trial
1000 square meters of GMP like pilot plant put into operation
Identified as “Shanghai High-Tech Enterprise”
Reorganization of Bioraylab and establishment of "Shanghai Research Center for Gene Editing and Cell Therapy"
BRL Medicine Inc. was incorporated
World's first successful application of CRISPR/Cas9 for mammalian gene editing, published by Nature Biotechnology, published by Nature Biotechnology